SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
Abeona Therapeutics Inc (NASDAQ: ABEO) had its price target lowered by analysts at Cantor Fitzgerald from $28.00 to $21.00. They now have an "overweight" rating on the stock.
Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO